Life Cycle Investment Partners’s ADMA Biologics ADMA Stock Holding History

Life Cycle Investment Partners’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$12.7M	Buy	+1,522,981	New	+$13.9M	0.06%	140

Other funds holding ADMA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Life Cycle Investment Partners's ADMA Position: Q2 2026 in Review

Life Cycle Investment Partners opened a new position in ADMA Biologics (ADMA) in Q2 2026: 1,522,981 shares worth $12.7M. The stake represents 0.06% of the portfolio and ranks #140 among its holdings.

203 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

Life Cycle Investment Partners held 1,522,981 shares of ADMA Biologics worth $12.7M as of Q2 2026.
ADMA Biologics was a new Life Cycle Investment Partners position in Q2 2026.
ADMA Biologics made up 0.06% of Life Cycle Investment Partners's portfolio in Q2 2026, its #140 holding.
203 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Life Cycle Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.